<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Central sleep apnea: Risk factors, clinical presentation, and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Central sleep apnea: Risk factors, clinical presentation, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Central sleep apnea: Risk factors, clinical presentation, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">M Safwan Badr, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ronald D Chervin, MD, MS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H17199584"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Central sleep apnea (CSA) is a disorder characterized by repetitive cessation or decrease of both airflow and ventilatory effort during sleep. CSA is less common than obstructive sleep apnea (OSA) and is often associated with other medical conditions, especially heart failure, stroke, and opioid medications. Rare cases are primary or idiopathic.</p><p>CSA can alternatively be categorized as hyperventilation- or hypoventilation-related. Hyperventilation-related CSA encompasses most of the types of CSA mentioned above; a notable exception is CSA associated with a drug or substance. Hypoventilation-related CSA occurs in disorders in which there is alveolar hypoventilation that is so severe that central apneas occur when the patient falls asleep because the wakefulness stimulus to breathe disappears. Central apneas tend to be a minor component of such disorders. Examples of contexts in which hypoventilation-related CSA may occur include central nervous system diseases, central nervous system suppressing drugs or substances, neuromuscular diseases, and severe abnormalities in pulmonary mechanics (eg, kyphoscoliosis). (See  <a class="medical medical_review" href="/d/html/7699.html" rel="external">"Central sleep apnea: Pathogenesis", section on 'Hyperventilation-related central apnea'</a> and  <a class="medical medical_review" href="/d/html/7699.html" rel="external">"Central sleep apnea: Pathogenesis", section on 'Hypoventilation-related central apnea'</a>.)</p><p>The clinical presentation and diagnosis of hyperventilation-related CSA are reviewed here. Hypoventilation-related CSA is not discussed here because central apneas tend to be a minor component of the underlying condition and, therefore, the presentation and diagnosis are dictated by the underlying condition. The pathogenesis and treatment of CSA are discussed separately. (See  <a class="medical medical_review" href="/d/html/7699.html" rel="external">"Central sleep apnea: Pathogenesis"</a> and  <a class="medical medical_review" href="/d/html/7675.html" rel="external">"Central sleep apnea: Treatment"</a>.)</p><p class="headingAnchor" id="H799740496"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>CSA is common, although less prevalent in the general population than obstructive sleep apnea (OSA). In a population-based study that included 5804 community-dwelling adults aged 40 years and older, the overall prevalence of CSA on polysomnography was 0.9 percent [<a href="#rid1">1</a>]. Approximately half of the CSA cases were associated with Cheyne-Stokes breathing (0.4 percent overall). The median age of patients with CSA was 69 years. CSA was more common among patients with heart failure (4.8 percent) and in males compared with females (1.8 versus 0.2 percent).</p><p class="headingAnchor" id="H3"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>The prevalence of symptomatic CSA (ie, CSA syndrome) appears to be higher among older adults, males, those with certain comorbid medical conditions such as heart failure, and patients who chronically use opioids [<a href="#rid2">2,3</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Age</span><span class="headingEndMark"> — </span>The prevalence of CSA syndrome is greater among adults who are older than 65 years than among younger adults (1.1 versus 0.4 percent), according to an observational study of 741 randomly selected adults that defined CSA syndrome as a central apnea-hypopnea index ≥10 events per hour plus symptoms or signs of disrupted sleep (eg, daytime sleepiness) [<a href="#rid4">4</a>]. The study also found that 12 percent of the adults older than 65 years had ≥2.5 central apneas per hour of sleep compared with only 1.7 percent of younger adults.</p><p>The increased prevalence of CSA syndrome among older adults may reflect the higher frequency of comorbid conditions that influence breathing during sleep among older adults, such as heart failure [<a href="#rid5">5</a>], atrial fibrillation [<a href="#rid6">6</a>], and cerebrovascular diseases [<a href="#rid7">7,8</a>]. Alternatively, it may be due to the aging process itself or to sleep state oscillation precipitating central apnea [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/d/html/7699.html" rel="external">"Central sleep apnea: Pathogenesis", section on 'Sleep-onset central apneas'</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Sex</span><span class="headingEndMark"> — </span>CSA syndrome is more prevalent among males than females. In one population-based sample, the prevalence of CSA syndrome was 0.4 percent among males and 0 percent among females, while central apneas were detected in 7.8 percent of males and only 0.3 percent of females [<a href="#rid10">10</a>]. Experimentally, the propensity for developing hypocapnic central apnea is greater in males compared with females [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/d/html/7699.html" rel="external">"Central sleep apnea: Pathogenesis"</a>.)</p><p>The difference in CSA propensity between sexes may relate to the effects of both testosterone and estrogens on apneic threshold. Administration of testosterone to healthy premenopausal females for 12 days increases the apneic threshold during non-rapid eye movement (NREM) sleep [<a href="#rid12">12</a>], whereas suppression of testosterone with <a class="drug drug_general" data-topicid="9549" href="/d/drug information/9549.html" rel="external">leuprolide</a> acetate in healthy males decreases the apneic threshold [<a href="#rid13">13</a>]. In a separate study, there was no difference in carbon dioxide reserve between males and postmenopausal females during NREM sleep, whereas administration of hormone replacement therapy in females increased carbon dioxide reserve (reflecting lower susceptibility to central apnea) [<a href="#rid14">14</a>]. </p><p class="headingAnchor" id="H6"><span class="h2">Heart failure</span><span class="headingEndMark"> — </span>Both CSA associated with Cheyne-Stokes breathing, and obstructive sleep apnea (OSA) are prevalent among patients with heart failure [<a href="#rid5">5,15-17</a>]. The former is particularly common among individuals with heart failure who are male, older than 60 years, have atrial fibrillation, or have daytime hypocapnia (PaCO<sub>2</sub> &lt;38 mmHg) [<a href="#rid18">18</a>]. CSA and OSA in patients with heart failure are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/7682.html" rel="external">"Sleep-disordered breathing in heart failure"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Stroke</span><span class="headingEndMark"> — </span>CSA is common after stroke [<a href="#rid7">7,19</a>]. This was illustrated by a prospective cohort study of 161 patients who had a stroke. Approximately 70 percent of patients developed sleep apnea (defined as an apnea-hypopnea index &gt;10 events per hour) within the initial 72 hours, including 26 percent with CSA in the context of Cheyne-Stokes breathing. Three months later, CSA was detected in only 7 percent of the patients, suggesting that CSA following acute stroke is often self-limited. There was no relationship between the location of the stroke and the likelihood of sleep apnea. The diagnosis and management of sleep apnea in patients with stroke is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7716.html" rel="external">"Sleep-related breathing disorders and stroke"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Other medical conditions</span><span class="headingEndMark"> — </span>CSA appears to be common among patients with certain medical conditions, including acromegaly [<a href="#rid20">20,21</a>], renal failure [<a href="#rid22">22</a>], atrial fibrillation [<a href="#rid2">2,23</a>], low cervical tetraplegia [<a href="#rid24">24</a>], and primary mitochondrial diseases [<a href="#rid25">25</a>]. </p><p class="headingAnchor" id="H3617770044"><span class="h2">Medications</span><span class="headingEndMark"> — </span>CSA occurs with increased frequency in patients who chronically use opioids, including <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> maintenance therapy. Concomitant benzodiazepines, which blunt the arousal response to hypoxia and hypercapnia during sleep, antidepressants, and gabapentinoid drugs may be associated with increased risk. High doses of <a class="drug drug_general" data-topicid="9062" href="/d/drug information/9062.html" rel="external">baclofen</a> have also been associated with CSA through central nervous system depressant effects [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/d/html/97859.html" rel="external">"Sleep-disordered breathing in patients chronically using opioids"</a>.)</p><p>Other medications may increase the activity of respiratory centers or generate respiratory instability, resulting in or aggravating hyperventilation-associated CSA [<a href="#rid3">3</a>]. There are rare reports of CSA associated with <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a>, a P2Y12 receptor antagonist, possibly through an effect on pulmonary C fibers [<a href="#rid3">3,27-30</a>].</p><p class="headingAnchor" id="H4409381"><span class="h1">CLINICAL FINDINGS</span><span class="headingEndMark"> — </span>The clinical features of CSA may be elucidated by a medical history, physical examination, or routine inpatient monitoring.</p><p class="headingAnchor" id="H26263960"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>Patients with CSA typically present with symptoms of disrupted sleep, such as excessive daytime sleepiness, poor subjective sleep quality, insomnia, inattention, and poor concentration. They may also report symptoms due to the recurrent central apneas with oxyhemoglobin desaturation, including paroxysmal nocturnal dyspnea, morning headaches, and nocturnal angina. These may be the presenting complaints, reported during the evaluation of another complaint, or detected during health maintenance screening. Alternatively, CSA may be first suspected when a hospitalized patient is being monitored and is noted to have episodic oxyhemoglobin desaturation, pauses in breathing, or nocturnal arrhythmias. (See  <a class="medical medical_review" href="/d/html/106476.html" rel="external">"Obstructive sleep apnea and other sleep disorders in hospitalized adults", section on 'Central sleep apnea'</a>.) </p><p class="headingAnchor" id="H4409547"><span class="h2">History</span><span class="headingEndMark"> — </span>Excessive daytime sleepiness is a common feature of CSA. However, it may go unnoticed or its significance may be underestimated because of its insidious onset and chronicity. Therefore, careful questioning is essential to uncover subtle drowsiness in boring, passive, or monotonous situations, such as driving, watching television, and reading. Excessive daytime sleepiness may not be present and is not a required feature of CSA, as some patients complain instead of insomnia due to the repetitive awakenings. </p><p>In addition to daytime sleepiness, the clinician should ask about other symptoms of disrupted sleep, such as poor subjective sleep quality, fatigue, inattention, poor concentration, moodiness, decreased libido, and impotence. Patients may complain of paroxysmal nocturnal dyspnea due to the compensatory hyperpnea that follows a central apnea, or they may report morning headaches and nocturnal angina due to the episodic oxyhemoglobin desaturation. Bed partners may report apneic periods.</p><p>CSA is typically associated with another medical condition and, therefore, patients often report the symptoms of the coexisting condition. As an example, patients with CSA associated with Cheyne-Stokes breathing may report symptoms of heart failure, such as dyspnea on exertion, orthopnea, and paroxysmal nocturnal dyspnea. When the CSA occurs in the context of Cheyne-Stokes breathing, the bed partner may report episodic hyperpnea, hypopnea, and apneic periods.</p><p class="headingAnchor" id="H4409554"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>There are no physical findings that are specific for CSA. However, patients who have CSA associated with another condition typically have physical findings due to the associated condition. As examples, patients with CSA associated with Cheyne-Stokes breathing due to heart failure frequently have peripheral edema, crackles, an S3 gallop, jugular venous distension, or right upper quadrant pain due to hepatic congestion, while patients with CSA associated with stroke may have asymmetric weakness, sensory or cranial nerve abnormalities, or ataxia. Many patients with CSA have an irregularly irregular pulse due to atrial fibrillation [<a href="#rid6">6</a>]. </p><p class="headingAnchor" id="H4409758"><span class="h2">Monitoring data</span><span class="headingEndMark"> — </span>Hospitalized patients who are being monitored may exhibit abnormalities due to CSA. Among the more common monitoring abnormalities are episodic apneic periods detected by a respiratory monitor, episodic oxyhemoglobin desaturation detected by continuous pulse oximetry, atrial fibrillation detected by telemetry while the patient is asleep or awake, and nocturnal arrhythmias detected by telemetry. While such monitoring data are not specific enough to confirm or exclude CSA, they warrant consideration of CSA, particularly when risk factors for CSA exist. (See  <a class="medical medical_review" href="/d/html/106476.html" rel="external">"Obstructive sleep apnea and other sleep disorders in hospitalized adults", section on 'Central sleep apnea'</a>.) </p><p class="headingAnchor" id="H2828544664"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>CSA should be suspected in patients with unexplained daytime sleepiness and risk factors for CSA, such as heart failure or use of opioids. Diagnosis requires a high index of suspicion, confirmation of central apneas on in-laboratory polysomnography (PSG), and at least one compatible symptom or consequence of the apnea syndrome.</p><p class="headingAnchor" id="H10"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>Patients with daytime sleepiness plus risk factors for CSA (eg, heart failure, stroke, use of a long-acting opioid) or more than one symptom or sign of CSA (eg, daytime sleepiness, insomnia, morning headaches, nocturnal angina, witnessed pauses in breathing during sleep) should undergo full-night, attended, in-laboratory PSG. PSG is considered the gold standard diagnostic test for sleep-related breathing disorders. Ambulatory diagnosis and management, including home sleep apnea testing, have not been validated for the management of CSA. </p><p>During PSG, the patient is connected to a variety of monitoring devices. Physiologic variables are recorded digitally on a paperless computerized system while the patient sleeps and during any intervening wakefulness. Captured information includes sleep stages (via electroencephalography, electrooculography, submental electromyography), respiratory effort (usually via respiratory inductive plethysmography, sometimes with electromyography, strain gauges, piezo electrodes, or impedance devices), airflow (usually via a nasal pressure transducer and oronasal thermistor), oxyhemoglobin saturation (via continuous pulse oximetry), and heart rate and rhythm (via continuous electrocardiography). The sleeping room is usually equipped with an infrared camera and audio system that allows the technologist to see, hear, and communicate with the patient without entering the bedroom. Patterns of physiologic abnormalities during sleep are often diagnostic. (See  <a class="medical medical_review" href="/d/html/7696.html" rel="external">"Overview of polysomnography in adults"</a> and  <a class="medical medical_review" href="/d/html/99553.html" rel="external">"Polysomnography in the evaluation of sleep-disordered breathing in adults"</a>.)</p><p class="headingAnchor" id="H4409791"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>The diagnostic criteria for CSA vary according to the type of CSA [<a href="#rid31">31</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Primary CSA requires the following four findings:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Polysomnography (PSG) reveals ≥5 central apneas and/or central hypopneas per hour of sleep; the number of central apneas plus central hypopneas is &gt;50 percent of the total number of apneas and hypopneas; and there is no evidence of Cheyne-Stokes breathing.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The patient reports sleepiness; awakening short of breath; witnessed apneas; or difficulty initiating or maintaining sleep, frequent awakenings or nonrestorative sleep.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There is no evidence of daytime or nocturnal hypoventilation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The disorder is not better explained by another current sleep disorder, medical disorder, medication, or substance use. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CSA with Cheyne-Stokes breathing requires the following four findings:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>PSG reveals ≥5 central apneas and/or central hypopneas per hour of sleep; there are at least three consecutive central apneas and/or central hypopneas separated by a crescendo-decrescendo change in breathing amplitude with a cycle length of ≥40 seconds (ie, Cheyne-Stokes breathing pattern) [<a href="#rid32">32</a>]; and the number of central apneas and/or central hypopneas is &gt;50 percent of the total number of apneas and hypopneas.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The patient reports sleepiness; awakening with shortness of breath; witnessed apneas; or difficulty initiating or maintaining sleep or nonrestorative sleep.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The patient has atrial fibrillation/flutter, congestive heart failure, or a neurological disorder.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The disorder is not better explained by another current sleep disorder, medication (eg, opioids), or substance use. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CSA due to high altitude periodic breathing requires the following four findings:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The breathing disturbance occurs at high altitude (typically at least 2500 meters, although some individuals may exhibit the disorder at altitudes as low as 1500 meters).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The patient reports sleepiness; awakening with shortness of breath or morning headache; or difficulty initiating or maintaining sleep, frequent awakenings, or nonrestorative sleep.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Witnessed periodic breathing, or PSG if performed at altitude reveals recurrent central apneas or hypopneas with a frequency of ≥5 events per hour.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The disorder is not better explained by another current sleep disorder, medical disorder, medication (eg, opioids), or substance use. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CSA due to a medication or substance requires the following four findings:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The patient is taking an opioid, <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a>, or other medication known to impact respiratory control.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The patient reports sleepiness; awakening short of breath; witnessed apneas; or difficulty initiating or maintaining sleep, frequent awakenings, or nonrestorative sleep.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>PSG reveals ≥5 central apneas and/or central hypopneas per hour of sleep; the number of central apneas plus central hypopneas is &gt;50 percent of the total number of apneas and hypopneas.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The disorder is not better explained by another current sleep disorder or medical disorder.</p><p></p><p>Central apneas and hypopneas are defined separately. (See  <a class="medical medical_review" href="/d/html/99553.html" rel="external">"Polysomnography in the evaluation of sleep-disordered breathing in adults"</a>.)</p><p class="headingAnchor" id="H811984224"><span class="h2">Caveats and limitations</span></p><p class="bulletIndent1"><span class="glyph">●</span>Existing diagnostic criteria address CSA as a sole condition. However, "pure" CSA is uncommon, as more than 50 percent of patients with CSA have comorbid obstructive sleep apnea (OSA). With increasing rates of obesity, the prevalence of comorbid OSA due to a compromised upper airway may be increasing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CSA is variably defined in clinical research. Many studies use a simple definition (ie, &gt;5 central apnea events per hour), while others also require that the number of central apneas/hypopneas exceeds 50 percent of the total apneas/hypopneas, as per ICSD-3-TR criteria. Use of the ICSD-3-TR criteria may exclude some patients who have meaningful CSA, because some laboratories do not subclassify hypopneas or they count all hypopneas as obstructive. One particular group that may be misclassified is premenopausal females, who are relatively resistant to central apneas and may develop mostly central hypopneas, which may be lumped under obstructive hypopneas.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subclassification of CSA according to type or predisposing factor is also variable, and published studies may not follow the taxonomy used by the ICSD-3-TR. Many studies include any CSA, while others focus on one specific entity, such as CSA due to heart failure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Studies investigating primary CSA are uncommon and may not be based on thorough assessment of cardiac function and exclusion of opioid use. Similarly, CSA secondary to medication is heterogeneous and may be hypoventilation or hyperventilation related.</p><p></p><p class="headingAnchor" id="H4409823"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>A variety of conditions must be considered in the differential diagnosis of CSA because they similarly cause excessive daytime sleepiness and other symptoms and signs of disrupted sleep. All of these conditions are distinguished via polysomnography:</p><p class="bulletIndent1"><span class="glyph">●</span>Obstructive sleep apnea (OSA) – OSA is a disorder that is characterized by repetitive obstructive apneas and hypopneas caused by complete or partial collapse of the upper airway during sleep. These obstructive events typically lead to awakenings, resulting in symptoms and signs of disrupted sleep. Among the disorders in the differential diagnosis of CSA, OSA is the most closely related because only CSA and OSA are characterized by symptoms and signs of episodic oxyhemoglobin desaturation (eg, morning headaches). (See  <a class="medical medical_review" href="/d/html/7706.html" rel="external">"Clinical presentation and diagnosis of obstructive sleep apnea in adults"</a> and  <a class="medical medical_review" href="/d/html/7695.html" rel="external">"Obstructive sleep apnea: Overview of management in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Periodic limb movements of sleep (PLMS) – PLMS are recurrent jerks of the legs and arms that can occur in association with arousals. When PLMS are excessive, symptoms can include insomnia or daytime sleepiness. (See  <a class="medical medical_review" href="/d/html/4892.html" rel="external">"Clinical features and diagnosis of restless legs syndrome and periodic limb movement disorder in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rotating shift workers – Night-shift workers obtain approximately seven hours per week less sleep than non-shift workers. They often revert to a daytime schedule on their leisure days, which adds to their sleep deprivation and daytime sleepiness. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Narcolepsy – Narcolepsy is a clinical syndrome of excess daytime sleepiness. Additional features may include cataplexy, hypnagogic hallucinations, sleep attacks (episodes of sudden need to lie down and sleep), and sleep paralysis. Although these additional features are classically described, a wide spectrum of clinical presentations exists [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/d/html/7689.html" rel="external">"Clinical features and diagnosis of narcolepsy in adults"</a> and  <a class="medical medical_review" href="/d/html/7681.html" rel="external">"Treatment of narcolepsy in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory disease – Patients with either chronic obstructive lung disease or restrictive lung disease may have sleep-related hypoventilation with desaturation, resulting in sudden awakenings and dyspnea that imitate CSA. Patients with neuromuscular disease depend on their accessory muscles to breathe and the inhibition of muscle activity during rapid eye movement (REM) sleep can cause hypoventilation with profound desaturations and awakenings. Poorly controlled asthma is often worse at night, with nocturnal bronchospasm and cough inducing sleep fragmentation and paroxysmal dyspnea.</p><p></p><p class="headingAnchor" id="H3671968554"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113310.html" rel="external">"Society guideline links: Sleep-related breathing disorders in adults"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Central sleep apnea (CSA) is a disorder characterized by repetitive cessation or decrease of both airflow and ventilatory effort during sleep. It can be primary (ie, idiopathic CSA) or secondary. Secondary CSA can occur, for example, in association with Cheyne-Stokes breathing, a medical condition, a drug or substance, or high altitude periodic breathing. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – CSA is uncommon in the general population; however, its prevalence is higher among older adults, males, and those with certain comorbid conditions, such as heart failure or stroke. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Patients with CSA typically present with symptoms of disrupted sleep (eg, excessive daytime sleepiness, poor subjective sleep quality, insomnia, inattention, and poor concentration) and/or symptoms due to recurrent central apneas with oxyhemoglobin desaturation (eg, paroxysmal nocturnal dyspnea, morning headaches, and nocturnal angina). (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation </strong>– Patients with daytime sleepiness plus risk factors for CSA (eg, heart failure, stroke, chronic opioid therapy) or more than one symptom or sign of CSA (eg, daytime sleepiness, insomnia, morning headaches, nocturnal angina, witnessed pauses in breathing during sleep) should undergo full-night, attended, in-laboratory polysomnography (PSG). PSG is considered the gold standard diagnostic test for sleep-related breathing disorders. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnostic criteria for CSA vary according to the type of CSA. Generally speaking, diagnosis generally requires evidence of frequent central apneas via polysomnography, symptoms or signs of disrupted sleep, association with an underlying cause, and exclusion of alternative diagnoses. (See <a class="local">'Diagnostic criteria'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – A variety of conditions must be considered in the differential diagnosis of CSA because they similarly cause excessive daytime sleepiness and other symptoms and signs of disrupted sleep. All of these conditions are distinguished by polysomnography. They include obstructive sleep apnea, periodic limb movements of sleep, shift work, narcolepsy, and respiratory disease. (See <a class="local">'Differential diagnosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Donovan LM, Kapur VK. Prevalence and Characteristics of Central Compared to Obstructive Sleep Apnea: Analyses from the Sleep Heart Health Study Cohort. Sleep 2016; 39:1353.</a></li><li><a class="nounderline abstract_t">Ratz D, Wiitala W, Badr MS, et al. Correlates and consequences of central sleep apnea in a national sample of US veterans. Sleep 2018; 41.</a></li><li><a class="nounderline abstract_t">Baillieul S, Revol B, Jullian-Desayes I, et al. Diagnosis and management of central sleep apnea syndrome. Expert Rev Respir Med 2019; 13:545.</a></li><li><a class="nounderline abstract_t">Bixler EO, Vgontzas AN, Ten Have T, et al. Effects of age on sleep apnea in men: I. Prevalence and severity. Am J Respir Crit Care Med 1998; 157:144.</a></li><li><a class="nounderline abstract_t">Bradley TD, Floras JS. Sleep apnea and heart failure: Part II: central sleep apnea. Circulation 2003; 107:1822.</a></li><li><a class="nounderline abstract_t">Leung RS, Huber MA, Rogge T, et al. Association between atrial fibrillation and central sleep apnea. Sleep 2005; 28:1543.</a></li><li><a class="nounderline abstract_t">Bassetti C, Aldrich MS. Sleep apnea in acute cerebrovascular diseases: final report on 128 patients. Sleep 1999; 22:217.</a></li><li><a class="nounderline abstract_t">Johnson KG, Johnson DC. Frequency of sleep apnea in stroke and TIA patients: a meta-analysis. J Clin Sleep Med 2010; 6:131.</a></li><li><a class="nounderline abstract_t">Pack AI, Silage DA, Millman RP, et al. Spectral analysis of ventilation in elderly subjects awake and asleep. J Appl Physiol (1985) 1988; 64:1257.</a></li><li><a class="nounderline abstract_t">Bixler EO, Vgontzas AN, Lin HM, et al. Prevalence of sleep-disordered breathing in women: effects of gender. Am J Respir Crit Care Med 2001; 163:608.</a></li><li><a class="nounderline abstract_t">Skatrud JB, Dempsey JA. Interaction of sleep state and chemical stimuli in sustaining rhythmic ventilation. J Appl Physiol Respir Environ Exerc Physiol 1983; 55:813.</a></li><li><a class="nounderline abstract_t">Zhou XS, Rowley JA, Demirovic F, et al. Effect of testosterone on the apneic threshold in women during NREM sleep. J Appl Physiol (1985) 2003; 94:101.</a></li><li><a class="nounderline abstract_t">Mateika JH, Omran Q, Rowley JA, et al. Treatment with leuprolide acetate decreases the threshold of the ventilatory response to carbon dioxide in healthy males. J Physiol 2004; 561:637.</a></li><li><a class="nounderline abstract_t">Rowley JA, Zhou XS, Diamond MP, Badr MS. The determinants of the apnea threshold during NREM sleep in normal subjects. Sleep 2006; 29:95.</a></li><li><a class="nounderline abstract_t">Javaheri S, Parker TJ, Liming JD, et al. Sleep apnea in 81 ambulatory male patients with stable heart failure. Types and their prevalences, consequences, and presentations. Circulation 1998; 97:2154.</a></li><li><a class="nounderline abstract_t">Javaheri S, Parker TJ, Wexler L, et al. Occult sleep-disordered breathing in stable congestive heart failure. Ann Intern Med 1995; 122:487.</a></li><li><a class="nounderline abstract_t">Javaheri S. Central sleep apnea-hypopnea syndrome in heart failure: prevalence, impact, and treatment. Sleep 1996; 19:S229.</a></li><li><a class="nounderline abstract_t">Sin DD, Fitzgerald F, Parker JD, et al. Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. Am J Respir Crit Care Med 1999; 160:1101.</a></li><li><a class="nounderline abstract_t">Bassetti C, Aldrich MS, Chervin RD, Quint D. Sleep apnea in patients with transient ischemic attack and stroke: a prospective study of 59 patients. Neurology 1996; 47:1167.</a></li><li><a class="nounderline abstract_t">Grunstein RR, Ho KY, Berthon-Jones M, et al. Central sleep apnea is associated with increased ventilatory response to carbon dioxide and hypersecretion of growth hormone in patients with acromegaly. Am J Respir Crit Care Med 1994; 150:496.</a></li><li><a class="nounderline abstract_t">Grunstein RR, Ho KY, Sullivan CE. Sleep apnea in acromegaly. Ann Intern Med 1991; 115:527.</a></li><li><a class="nounderline abstract_t">Hanly PJ, Pierratos A. Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med 2001; 344:102.</a></li><li><a class="nounderline abstract_t">Mehra R, Stone KL, Varosy PD, et al. Nocturnal Arrhythmias across a spectrum of obstructive and central sleep-disordered breathing in older men: outcomes of sleep disorders in older men (MrOS sleep) study. Arch Intern Med 2009; 169:1147.</a></li><li><a class="nounderline abstract_t">Sankari A, Bascom A, Oomman S, Badr MS. Sleep disordered breathing in chronic spinal cord injury. J Clin Sleep Med 2014; 10:65.</a></li><li><a class="nounderline abstract_t">Ramezani RJ, Stacpoole PW. Sleep disorders associated with primary mitochondrial diseases. J Clin Sleep Med 2014; 10:1233.</a></li><li><a class="nounderline abstract_t">Revol B, Jullian-Desayes I, Bailly S, et al. Baclofen and sleep apnoea syndrome: analysis of VigiBase, the WHO pharmacovigilance database. Eur Respir J 2018; 51.</a></li><li><a class="nounderline abstract_t">Giannoni A, Emdin M, Passino C. Cheyne-Stokes Respiration, Chemoreflex, and Ticagrelor-Related Dyspnea. N Engl J Med 2016; 375:1004.</a></li><li><a class="nounderline abstract_t">Lamberts A, Euverman HI, Terra JB, et al. Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases. Front Immunol 2018; 9:248.</a></li><li><a class="nounderline abstract_t">Revol B, Jullian-Desayes I, Tamisier R, et al. Ticagrelor and Central Sleep Apnea. J Am Coll Cardiol 2018; 71:2378.</a></li><li><a class="nounderline abstract_t">Paboeuf C, Priou P, Meslier N, et al. Ticagrelor-Associated Shift From Obstructive to Central Sleep Apnea: A Case Report. J Clin Sleep Med 2019; 15:1179.</a></li><li class="breakAll">American Academy of Sleep Medicine. International Classification of Sleep Disorders, 3rd ed, text revision, American Academy of Sleep Medicine, 2023.</li><li class="breakAll">Troester MM, Quan SF, Berry RB, et al. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications, Version 3, American Academy of Sleep Medicine, 2023.</li><li><a class="nounderline abstract_t">Black JE, Brooks SN, Nishino S. Conditions of primary excessive daytime sleepiness. Neurol Clin 2005; 23:1025.</a></li></ol></div><div id="topicVersionRevision">Topic 7701 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27166235" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Prevalence and Characteristics of Central Compared to Obstructive Sleep Apnea: Analyses from the Sleep Heart Health Study Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29608761" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Correlates and consequences of central sleep apnea in a national sample of US veterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31014146" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Diagnosis and management of central sleep apnea syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9445292" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Effects of age on sleep apnea in men: I. Prevalence and severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12682029" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Sleep apnea and heart failure: Part II: central sleep apnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16408413" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Association between atrial fibrillation and central sleep apnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10201066" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Sleep apnea in acute cerebrovascular diseases: final report on 128 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20411688" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Frequency of sleep apnea in stroke and TIA patients: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3366740" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Spectral analysis of ventilation in elderly subjects awake and asleep.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11254512" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prevalence of sleep-disordered breathing in women: effects of gender.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6415011" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Interaction of sleep state and chemical stimuli in sustaining rhythmic ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12391093" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effect of testosterone on the apneic threshold in women during NREM sleep.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15375194" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Treatment with leuprolide acetate decreases the threshold of the ventilatory response to carbon dioxide in healthy males.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16453986" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The determinants of the apnea threshold during NREM sleep in normal subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9626176" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Sleep apnea in 81 ambulatory male patients with stable heart failure. Types and their prevalences, consequences, and presentations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7872582" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Occult sleep-disordered breathing in stable congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9085518" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Central sleep apnea-hypopnea syndrome in heart failure: prevalence, impact, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10508793" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8909424" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Sleep apnea in patients with transient ischemic attack and stroke: a prospective study of 59 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8049836" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Central sleep apnea is associated with increased ventilatory response to carbon dioxide and hypersecretion of growth hormone in patients with acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1883121" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Sleep apnea in acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11150360" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19546416" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Nocturnal Arrhythmias across a spectrum of obstructive and central sleep-disordered breathing in older men: outcomes of sleep disorders in older men (MrOS sleep) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24426822" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Sleep disordered breathing in chronic spinal cord injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25325607" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Sleep disorders associated with primary mitochondrial diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29326335" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Baclofen and sleep apnoea syndrome: analysis of VigiBase, the WHO pharmacovigilance database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27602681" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cheyne-Stokes Respiration, Chemoreflex, and Ticagrelor-Related Dyspnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29520266" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29773166" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Ticagrelor and Central Sleep Apnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31482841" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Ticagrelor-Associated Shift From Obstructive to Central Sleep Apnea: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31482841" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Ticagrelor-Associated Shift From Obstructive to Central Sleep Apnea: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31482841" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Ticagrelor-Associated Shift From Obstructive to Central Sleep Apnea: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16243614" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Conditions of primary excessive daytime sleepiness.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
